Want to see AARD full AI Analyst Report?
AARD Stock Chart & Stats
$5.23
--
Market closed
$5.23
--
Day’s Range― - ―
52-Week Range$3.35 - $17.94
Previous CloseN/A
VolumeN/A
Average Volume (3M)168.54K
Market Cap
$124.74M
Enterprise Value$21.24M
Total Cash (Recent Filing)$91.20M
Total Debt (Recent Filing)$336.00K
Price to Earnings (P/E)―
Beta2.18
Next Earnings
Aug 19, 2026EPS Estimate
-0.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.21
Shares Outstanding21,884,157
10 Day Avg. Volume123,995
30 Day Avg. Volume168,536
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)2.69
Price to Sales (P/S)0.00
P/FCF Ratio-5.28
Enterprise Value/Market Cap0.17
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.30
Forecast
1Y Price Target
$5.00Price Target Upside-4.40% Downside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)-3.59
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low debt and restored positive equity materially reduce near-term solvency risk. This balance sheet cushion gives management optionality to fund operations, respond to the ARD-101 hold, and pursue non-dilutive or strategic options over the next several quarters without immediate refinancing pressure.
Management ContinuityStructured retention bonuses for key financial and clinical leaders help preserve institutional knowledge and execution capability during critical program decisions. Sustained leadership reduces execution risk when navigating regulatory responses and clinical strategy over a multi-quarter timeframe.
Near-term Cash RunwayReported cash and investments covering run to mid-2027 give the company time to unblind data, address FDA concerns, and evaluate development pathways. While burn is high, this liquidity provides a durable window to pursue technical fixes, additional data collection, or strategic alternatives without immediate insolvency risk.
Bears Say
Regulatory Setback (FDA Hold)A full clinical hold halts all dosing and enrollment, pausing the company’s primary path to approval. This introduces material timeline and evidentiary uncertainty, may require additional studies or protocol changes, and raises costs and strategic risk that will persist until hold conditions are resolved.
Pre-revenue, Widening LossesOperating losses have accelerated while revenue remains nil, meaning ongoing operations are financed by cash reserves or external funding. High real cash burn (not just non-cash losses) creates persistent capital dependency and likely dilution or difficult financing choices if clinical delays extend.
Single-program ConcentrationBusiness reliance on a single late-stage asset concentrates binary program risk: the outcome of ARD-101 will disproportionately determine the company’s future. A sustained delay or negative outcome leaves limited alternative revenue engines and forces strategic pivots that are costly and time consuming.
Aardvark Therapeutics, Inc. News
AARD FAQ
What was Aardvark Therapeutics, Inc.’s price range in the past 12 months?
Aardvark Therapeutics, Inc. lowest stock price was $3.35 and its highest was $17.94 in the past 12 months.
What is Aardvark Therapeutics, Inc.’s market cap?
Aardvark Therapeutics, Inc.’s market cap is $124.74M.
When is Aardvark Therapeutics, Inc.’s upcoming earnings report date?
Aardvark Therapeutics, Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 46 days.
How were Aardvark Therapeutics, Inc.’s earnings last quarter?
Aardvark Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$0.99 earnings per share for the quarter, missing the consensus estimate of -$0.877 by -$0.113.
Is Aardvark Therapeutics, Inc. overvalued?
According to Wall Street analysts Aardvark Therapeutics, Inc.’s price is currently Overvalued.
Does Aardvark Therapeutics, Inc. pay dividends?
Aardvark Therapeutics, Inc. does not currently pay dividends.
What is Aardvark Therapeutics, Inc.’s EPS estimate?
Aardvark Therapeutics, Inc.’s EPS estimate is -0.86.
How many shares outstanding does Aardvark Therapeutics, Inc. have?
Aardvark Therapeutics, Inc. has 21,884,157 shares outstanding.
What happened to Aardvark Therapeutics, Inc.’s price movement after its last earnings report?
Aardvark Therapeutics, Inc. reported an EPS of -$0.99 in its last earnings report, missing expectations of -$0.877. Following the earnings report the stock price went down -4.924%.
Which hedge fund is a major shareholder of Aardvark Therapeutics, Inc.?
Currently, no hedge funds are holding shares in AARD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aardvark Therapeutics, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.00 (-4.40% Downside)
$5.00 (-4.40% Downside)
Blogger Sentiment
Neutral
AARD Sentiment 50%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 8.8%
Last 30 Days ▼ 8.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.84%
12-Months-Change
Fundamentals
Return on Equity
-61.71%
Trailing 12-Months
Asset Growth
-37.21%
Trailing 12-Months
Company Description
Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders. The company's primary experimental drug, ARD-101, is an orally administered, gut-specific small molecule. It functions as an agonist, targeting particular bitter taste receptors found within the gut lumen. ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome. Additionally, it is in a Phase II trial for addressing hyperphagia linked to acquired hypothalamic obesity, often a result of craniopharyngioma treatments like surgery or radiation therapy. Aardvark Therapeutics is also advancing ARD-201, which is currently in Phase I clinical trials for the treatment of obesity. Established in 2017, the company is based in San Diego, California.
AARD Stock 12 Month Forecast
Average Price Target
$5.00
▼(-4.40% Downside)
Technical Analysis
Ownership Overview
14.33% Insiders
4.47% Mutual Funds
26.61% Other Institutional Investors
50.98% Public Companies and
Individual Investors